跳轉至內容
Merck
全部照片(1)

重要文件

SML0609

Sigma-Aldrich

Teniposide

≥97% (HPLC)

同義詞:

4′-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin, Tenoposide, VM-26

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C32H32O13S
CAS號碼:
分子量::
656.65
EC號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥97% (HPLC)

形狀

powder

光學活性

[α]/D -100 to -115°, c = 1 in chloroform/methanol (9:1)

顏色

white to beige

溶解度

DMSO: 10 mg/mL, clear

運輸包裝

wet ice

儲存溫度

−20°C

InChI

1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1

InChI 密鑰

NRUKOCRGYNPUPR-QBPJDGROSA-N

尋找類似的產品? 前往 產品比較指南

應用

Teniposide has been used as a topoisomerase II inhibitor to study its effects on the flagellum length in Trypanosoma brucei. It has also been used as a chemotherapeutic agent to study its interactions with piperazine(B87).

生化/生理作用

Teniposide (VM-26) is a Topoisomerase II inhibitor with antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, inducing breaks in double stranded DNA and preventing repair.
Teniposide is a derivative of podophyllotoxin and has been studied to treat several cancers. It acts during the late S phase or the early G2 phase of the cell cycle.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Carc. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 1

1 of 1

Mauro Pagani
The Medical clinics of North America, 94(4), 835-852 (2010-07-09)
The number of drugs used for the treatment of different types of cancers is constantly increasing and actually exceeds 100 distinct chemical formulations. The use of most cytotoxic agents is associated with potential hypersensitivity reactions, and the constant increase of
Suna He et al.
AAPS PharmSciTech, 13(3), 846-852 (2012-05-31)
In order to tackle the problems on low water solubility of teniposide, involvement of toxic surfactant in its injection, and the poor stability during infusion, a Cremophor-free teniposide self-microemulsified drug delivery system (TEN-SMEDDS) was prepared for the first time, characterized
Kaori Kadoyama et al.
Journal of experimental & clinical cancer research : CR, 30, 93-93 (2011-10-06)
Previously, adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) database were reviewed to confirm platinum agent-associated hypersensitivity reactions. The present study was performed to confirm whether the database could suggest the hypersensitivity reactions caused by
Michael J Joyce et al.
Journal of pediatric hematology/oncology, 35(1), 32-35 (2012-12-06)
Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis. In a previous study, 9 of 14 children with induction failure entered remission after teniposide (VM26) plus cytosine arabinoside (Ara-C). We attempted to confirm these results.
Baohong Wang et al.
Hematological oncology, 31(1), 29-33 (2012-04-11)
There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務